

Presented at: the 2017 Association for Research in Vision and Ophthalmology Annual Meeting, Global Connections in Vision Research, May 7–11, 2017, Baltimore, Maryland.

Financial Disclosure(s): The author(s) have made the following disclosure(s): P.A.K.: Speakers fees — Allergan, Novartis, Bayer, Heidelberg Engineering, Topcon, Haag-Streit; Consultant fees — Optos and DeepMind.

Supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. P.A.K. is supported by a Clinician Scientist Award (CS-2014-14-023) from the NIHR.

Author Contributions:

Conception and design: Van Bol, Keane, Pal, Sobha

Data collection: Van Bol, Kurt, Sobha

Analysis and interpretation: Van Bol, Kurt, Sobha

Obtained funding: Not applicable

Overall responsibility: Van Bol, Keane, Pal, Sobha

Correspondence:

Laure B. Van Bol, MD, Moorfields Eye Hospital, 162 City Road, London EC1V 2PD, United Kingdom. E-mail: [laure.vanbol@moorfields.nhs.uk](mailto:laure.vanbol@moorfields.nhs.uk) (L.B.Van Bol)

References

1. Gruener AM, Jeffries MAR, El Housseini Z, et al. Poppers maculopathy. *Lancet*. 2014;384:1606.
2. Vignal-Clermont C, Audo I, Sahel JA, et al. Poppers-associated retinal toxicity. *N Engl J Med*. 2010;363:1583-1585.
3. Isabelle Audo I, El Sanharawi M, Vignal-Clermont C, et al. Foveal damage in habitual poppers users. *Arch Ophthalmol*. 2011;129:703-708.
4. Pahlitzsch M, Mai C, Jousseaume AM, et al. Poppers maculopathy: complete restitution of macular changes in OCT after drug abstinence. *Semin Ophthalmol*. 2016;31:479-484.
5. Davies AJ, Kelly SP, Naylor SG, et al. Adverse ophthalmic reaction in poppers users: case series of “poppers maculopathy.” *Eye*. 2012;26:1479-1486.

## Corrigenda

The authors of “Factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or ranibizumab” (*Ophthalmology*. 2017;124:431-439) would like to make the following corrections to [Tables 1](#) and [2](#). Numbers in [Tables 1](#) and [2](#) were switched in error. The corrected tables appear below and the specific entries appear in bold.

The error was not replicated in the manuscript text and there are no substantive changes to the results of this article.



Table 1. Univariate Analyses of Baseline Characteristics as Potential Predictive Factors for PDR-worsening (Vitreous Hemorrhage, Retinal Detachment, Anterior Segment Neovascularization, or Neovascular Glaucoma)

Characteristic	Percentage of Eyes with an Event (No. of Eyes/Total)		P Value	Hazard Ratio (99% CI)
	Ranibizumab	PRP		
All eyes	30 (58/191)	37 (75/203)		
Gender				
Female	25 (21/83)	32 (29/92)	0.075	—
Male	34 (37/108)	41 (46/111)		1.42 (0.85–2.37)
Age (yrs)				
<50	28 (23/83)	44 (42/95)	0.014	1.16 (0.71–1.89)
≥50	32 (35/108)	31 (33/108)		—
Race/ethnicity*				
White	22 (22/100)	34 (34/101)	0.014	—
Nonwhite	40 (36/89)	40 (40/99)		1.61 (0.98–2.66)
Diabetes type†				
Type 1	28 (12/43)	44 (18/41)	0.82	1.05 (0.59–1.87)
Type 2	31 (44/140)	36 (56/155)		—
Duration of diabetes				
<20 years	29 (31/106)	36 (43/119)	0.67	—
≥20 years	32 (27/85)	38 (32/84)		1.07 (0.65–1.74)
HbA <sub>1c</sub> (%)‡				
<9	26 (28/106)	32 (32/101)	0.20	—
≥9	37 (29/78)	42 (41/97)		1.55 (0.94–2.56)

(Continued)

Table 1. (Continued.)

Characteristic	Percentage of Eyes with an Event (No. of Eyes/Total)		P Value	Hazard Ratio (99% CI)
	Ranibizumab	PRP		
Hypertension				
No	32 (20/63)	40 (25/62)	0.64	—
Yes	30 (38/128)	35 (50/141)		0.91 (0.53–1.55)
Visual acuity				
20/25 or better ( $\geq 79$ letters)	23 (20/87)	42 (39/93)	0.063	—
20/32 or worse ( $< 79$ letters)	37 (38/104)	33 (36/110)		1.17 (0.72–1.89)
Central subfield thickness (Stratus equivalent) <sup>§</sup>				
$< 250 \mu\text{m}$	27 (34/125)	41 (55/134)	0.88	1.00 (0.61–1.67)
$\geq 250 \mu\text{m}$	36 (23/64)	30 (20/67)		—
Vision-impairing center-involved-DME <sup>§</sup>				
No	28 (41/147)	40 (62/155)	0.85	—
Yes	38 (16/42)	28 (13/46)		0.96 (0.54–1.70)
Epiretinal membrane <sup>¶</sup>				
No	23 (19/84)	28 (28/101)	$< 0.001$	—
Yes	35 (34/97)	48 (45/93)		1.94 (1.17–3.19)
Vitreomacular traction <sup>  </sup>				
No	28 (33/118)	37 (53/145)	0.63	—
Yes	32 (19/59)	41 (21/51)		1.10 (0.67–1.80)
Neovascularization on clinical examination <sup>**</sup>				
NVD or NVE only	25 (29/114)	28 (35/125)	$< 0.001$	—
NVD and NVE	38 (27/71)	53 (39/74)		2.13 (1.34–3.39)
Diabetic retinopathy severity (ETDRS level) <sup>††</sup>				
Moderate PDR (level 65) or better	15 (17/117)	25 (31/125)	$< 0.001$	—
High-Risk PDR (level 71) or worse	57 (41/72)	58 (43/74)		3.97 (2.47–6.39)
Lens status				
Phakic	29 (50/170)	37 (70/187)	0.34	—
PC IOL	38 (8/21)	31 (5/16)		1.36 (0.59–3.12)
Vitreous hemorrhage at baseline				
No	25 (33/131)	29 (38/133)	$< 0.001$	—
Yes	42 (25/60)	53 (37/70)		2.28 (1.43–3.63)
PRP laser type <sup>‡‡</sup>				
Conventional single-spot		34 (56/164)	<b>0.018</b>	—
Pattern scan		49 (19/39)		1.87 (0.95–3.68)
Number of PRP spots <sup>‡‡</sup>				
Conventional single-spot $< 1400$ or pattern scan $< 2200$		<b>30 (29/98)</b>	0.19	— <sup>§§</sup>
Conventional single-spot $\geq 1400$ or pattern scan $\geq 2200$		<b>44 (46/105)</b>		1.49 (0.81–2.77)
Number of PRP sittings <sup>‡‡</sup>				
1		39 (42/109)	0.59	—
2 to 3		35 (33/94)		0.88 (0.49–1.60)

CI = confidence interval; CI-DME = center-involved diabetic macular edema; ETDRS = Early Treatment Diabetic Retinopathy Study; HbA<sub>1c</sub> = glycosylated hemoglobin; NVD = neovascularization of the disc; NVE = neovascularization elsewhere; OCT = optical coherence tomography; PDR = proliferative diabetic retinopathy; PRP = panretinal photocoagulation.

Dash marks (“—”) denote reference categories.

\*Race/ethnicity data missing for 2 eyes in ranibizumab group and 3 in PRP group.

†Diabetes type data missing for 8 eyes in ranibizumab group and 7 in PRP group.

‡HbA<sub>1c</sub> data missing for 7 eyes in ranibizumab group and 5 in PRP group.

§OCT central subfield thickness data missing for 2 eyes in each group.

¶Epiretinal membrane grading missing for 10 eyes in ranibizumab group and 9 in PRP group.

||Vitreomacular traction grading missing for 14 eyes in ranibizumab group and 7 in PRP group.

\*\*Neovascularization on clinical examination missing for 6 eyes in ranibizumab group and 4 in PRP group.

††DR severity (ETDRS) missing for 2 eyes in ranibizumab group and 4 in PRP group.

‡‡PRP group only.

§§Reference category is  $< 2200$  spots (if pattern scan) or  $< 1400$  spots (if conventional single-spot). These are median values rounded to the nearest hundred.

P value is from analysis with number of spots as continuous variable and controlling for PRP laser type.

Download English Version:

<https://daneshyari.com/en/article/5705169>

Download Persian Version:

<https://daneshyari.com/article/5705169>

[Daneshyari.com](https://daneshyari.com)